Clinical trials: Arsenic Trioxide
Myelodysplastic Syndromes, P53 Mutation
Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)
This is a prospective,controlled and multi-institution trial.The aim is to identify if using decitabine and Arsenic Trioxide(ATO) as the therapy of Myelodysplastic Syndrome(MDS) has better relapse free survival and complete…
- Trial name
- NCT03377725
- Testing
- Decitabine, Arsenic Trioxide
- Where
- 3 sites in China
- Sponsor
- Li Junmin
Myelodysplastic Syndrome (MDS)
Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)
In this phase II study besides evaluating for safety, the primary efficacy parameter is to evaluate the incidence of patients who have had a response to Trisenox by evidence of increased blood counts (red, white, or platelets)…
- Trial name
- NCT00225992
- Testing
- Arsenic Trioxide
- Where
- 2 sites in United States
- Sponsor
- Oncology Specialties, Alabama
Myelodysplastic Syndromes
Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndromes
This is a prospective, multicenter phase II trial designed to evaluate the safety and activity of the combination of association of arsenic trioxide (ATO) and ascorbic acid in patients with myelodysplastic syndromes
- Trial name
- NCT00803530
- Testing
- ATO + Ascorbic acid
- Where
- 13 sites in Italy
- Volunteers
- 55 people
- Sponsor
- Fondazione Italiana Sindromi Mielodisplastiche-ETS
Acute Promyelocytic Leukemia
Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
In this prospective randomized study for patients with newly diagnosed acute promyelocytic leukemia, patients will be randomized (1:1) into two groups which receive retinoic acid and arsenic trioxide based treatment versus…
- Trial name
- NCT01987297
- Testing
- ATRA+Arsenic, ATRA+Chemo
- Where
- China
- Volunteers
- 738 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Acute Promyelocytic Leukemia (APL)
Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia
Randomized, Open-Label Study to evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution (SDK001) under Fasting and Fed Conditions, to Compare to IV Arsenic Trioxide
- Trial name
- NCT06882031
- Testing
- Treatment A: Arsenic Trioxide (ATO) Intravenous, Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state, Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state
- Where
- Hong Kong
- Volunteers
- 12 people
- Sponsor
- SDK Therapeutics, Inc.
Leukemia
Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)
Several groups, especially the PETHEMA group (in their LPA96 and 99 trials), obtained low relapse rates in newly diagnosed Acute Promyelocytic Leukemia (APL) patients by combining ll-transretinoic acid (ATRA) and anthracyclines…
- Trial name
- Ara-C (NCT01191541)
- Testing
- DNR:, Ara-c
- Where
- 2 sites in China
- Volunteers
- 65 people
- Sponsor
- Xiaofan Zhu
Colorectal Cancer
Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00449137
- Testing
- Arsenic trioxide, Fluorouracil, Leucovorin calcium
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Miami
Adverse Reaction, Cardiotoxicity
Risk Analysis of Cardiotoxic Medication Use Due to Sodium Arsenite Chloride Injection
To study the current status of cardiotoxicity of arsenious acid by analyzing the literature, monitoring data, and real-world applications, and to discuss risk factors and preventive and control measures.
- Conditions
- Adverse Reaction, Cardiotoxicity, Evaluation Study
- Trial name
- NCT06060132
- Testing
- Sodium arsenite chloride injection
- Where
- 2 sites in China
- Volunteers
- 400 people
- Sponsor
- Qianfoshan Hospital
Acute Myelogenous Leukemia
Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia
This clinical research study is for patients with acute myelogenous leukemia (in short AML) that did not respond to previous treatment or unable to receive chemotherapy. Arsenic has been used as a drug for many centuries.
- Trial name
- NCT00184054
- Testing
- Arsenic Trioxide (ATO), Ascorbic Acid
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Southern California
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia
Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have relapsed or refractory lymphoma or leukemia.
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Prolymphocytic Leukemia, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
- Trial name
- NCT00005786
- Testing
- arsenic trioxide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma and Plasma Cell Neoplasm
Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, dexamethasone, and ascorbic acid, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00227682
- Testing
- ascorbic acid, arsenic trioxide, dexamethasone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Brain and Central Nervous System Tumors
Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as arsenic trioxide and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the…
- Trial name
- NCT00720564
- Testing
- arsenic trioxide, temozolomide, adjuvant therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Neuroblastoma
Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma
This clinical trial aims to explore and evaluate the efficacy and safety of combined chemotherapy with arsenic trioxide for stage 4/M neuroblastoma.
- Trial name
- NCT03503864
- Testing
- Arsenic Trioxide
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Yang Li
Leukemia, Myelodysplastic Syndromes
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
RATIONALE: Drugs used in chemotherapy, such as azacitidine and arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00234000
- Testing
- arsenic trioxide, azacitidine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00275067
- Testing
- arsenic trioxide, temozolomide, radiation therapy
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Northwestern University
Arsenic Trioxide, Childhood ALL
South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 Protocol
In recent years, the prognosis of pediatric relapsed ALL patients has improved, but the 5-year OS of patients with first recurrence is still less than 50%.
- Trial name
- SCCCG-R-ALL (NCT05682131)
- Testing
- Realgar Indigo naturalis formula, Conventional chemotherapy
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Pancreatic Cancer
Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have locally…
- Trial name
- NCT00053222
- Testing
- arsenic trioxide
- Where
- 11 sites in United States
- Volunteers
- 13 people
- Sponsor
- University of Chicago
Leukemia, Myelodysplastic Syndromes
Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00104806
- Testing
- cholecalciferol, arsenic trioxide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Wake Forest University Health Sciences
Acute Promyelocytic Leukemia
Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
Summary Acute promyelocytic leukemia is defined by a characteristic morphology (AML FAB M3/M3v), by the specific translocation t(15;17) and its molecular correlates (PML/RARa and RARa/PML).
- Trial name
- NCT00504764
- Testing
- Arsenic Trioxide, Autologous Transplantation, Allogenic Transplantation
- Where
- 86 sites in Spain
- Volunteers
- 60 people
- Sponsor
- PETHEMA Foundation
Myelodysplastic Syndrome
Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML
The purpose of this study is to find out the effectiveness and side effects of arsenic trioxide in combination with low-dose ara-C.
- Trial name
- NCT00195104
- Testing
- Arsenic Trioxide (Tricenox), Cytarabine
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Weill Medical College of Cornell University